Clinical Trial Update: Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating toripalimab plus axitinib as neoadjuvant therapy for advanced/metastatic non-clear cell renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Non-clear Cell Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: West China Hospital | Conditions: Neoadjuvant Therapy, Advanced Cancer | Phase 2 | Status: UNKNOWN